Significant weight gain in CLL patients treated with Ibrutinib: A potentially deleterious consequence of therapy
Open Access
- 17 October 2019
- journal article
- letter
- Published by Wiley in American Journal of Hematology
- Vol. 95 (1) , E16-E18
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute (F99CA222742)
- National Institutes of Health
This publication has 6 references indexed in Scilit:
- iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLLBlood, 2018
- Relationship between co‐morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort studyBritish Journal of Haematology, 2017
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2016
- Obesity in Adult Lymphoma SurvivorsLeukemia & Lymphoma, 2012
- Changes in Diet and Lifestyle and Long-Term Weight Gain in Women and MenNew England Journal of Medicine, 2011
- Overweight and Obesity as Determinants of Cardiovascular RiskArchives of internal medicine (1960), 2002